FDA doesn't approve most generics reviewed in first cycle

An HHS Office of Inspector General report says the FDA does not approve 96% of new generic drugs reviewed during their first cycle because they contain chemistry deficiencies. The document, which examines generic drug reviews for 2006, says the agency exceeded the 180-day review requirement for 46% of original applications. 
You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory